Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

EIT Pharma Closes Oversubscribed $35 Million Series A Round, Led by Propel Bio Partners. Proceeds will advance the company's late-stage infectious disease pipeline.

PRIVATEAug 31, 2026•8 days ago

Amount Raised

$35 Million

Round Type

Series A

Los AngelesBiotechnologyHealth CareTherapeutics

Investors

ArrowtownGood VenturesPropel Bio Partners

Description

EIT Pharma, Inc. has successfully closed an oversubscribed $35 million Series A financing round led by Propel Bio Partners. The funding aims to support the advancement of EIT Pharma's therapies for infectious diseases, particularly lonafarnib for chronic hepatitis D. In addition, it will aid in FDA review activities and future manufacturing and commercial readiness steps

Company Information

Company

EIT Pharma

Location

Los Angeles, California, United States

About

EIT Pharma is a biotechnology company focusing on developing therapies for infectious diseases. The company is dedicated to delivering life-changing therapies for patients with significant unmet medical needs. Their current projects include treatments for chronic hepatitis D and severe acute viral respiratory infections.

Don't miss EIT Pharma's next move

Get an email the moment EIT Pharma raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for EIT Pharma's next move

See what Strategic adds

Funding Insights

Based on industry data
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months
Monthly burn rate benchmark
47% of Series A startups spend $400k or more per month on operations
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

EIT Pharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.